Drug Profile

Intismeran autogene - Merck/Moderna Therapeutics

Alternative Names: mRNA-4157; mRNA-4157/V940; PCV; Personalised cancer vaccine - Moderna Therapeutics; V-940

Latest Information Update: 26 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Moderna Therapeutics
Developer Merck Sharp & Dohme; Moderna Therapeutics
Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Malignant melanoma; Non-small cell lung cancer
Phase II/III Squamous cell cancer
Phase II Bladder cancer; Renal cell carcinoma
No development reported Solid tumours

Most Recent Events

22 Oct 2026 Efficacy and adverse event data from a phase III trial in Malignant melanoma released by Merck & Co
30 Sep 2026 Moderna Therapeutics plans to launch intismeran autogene
19 Aug 2026 Efficacy data from a phase III INTerpath-001 trial in Malignant melanoma released by Moderna Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com